Department of Urology, Azienda Ospedaliero-Universitaria Policlinico S. Orsola-Malpighi, Bologna, Italy.
Clin Genitourin Cancer. 2013 Mar;11(1):5-9. doi: 10.1016/j.clgc.2012.09.010. Epub 2012 Oct 17.
Nephron-sparing surgery (NSS) for renal cell carcinoma (RCC) offers comparable oncologic results but a lower risk of chronic kidney disease when compared with radical nephrectomy; however it can result in positive surgical margins (PSMs) and consequently to a possible risk of oncologic failure. The aim of this review is to evaluate the incidence of PSMs after nephron-sparing surgery, to assess their clinical and oncologic impact, and to provide an overview of the possible therapeutic management. We performed a nonsystematic review of the literature in the MEDLINE database using the following keywords: partial nephrectomy, nephron-sparing surgery, and positive margin. We reviewed articles published only in English from January 2002 to May 2012. The overall incidence of PSMs after NSS ranges from 0% to 7%, with no significant differences in open, laparoscopic, and robot-assisted techniques. Smaller tumor size could result in a higher risk of PSMs. Even if there is not a clear agreement in the clinical evidence, local recurrence seems to be more likely in patients with PSMs, especially in those with high-grade tumors. Development of metastases and cancer-specific survival, as seen in midterm follow-up studies, seems to be comparable to those in patients with negative surgical margins. Considering the globally low risk of local recurrence, development of metastasis, or cancer-specific mortality, careful surveillance could be the best management option for most patients with PSMs after NSS.
保留肾单位手术(NSS)治疗肾细胞癌(RCC)在肿瘤学效果上与根治性肾切除术相当,但发生慢性肾脏病的风险更低;然而,它可能导致阳性手术切缘(PSMs),从而可能导致肿瘤学失败。本综述旨在评估保留肾单位手术后 PSMs 的发生率,评估其临床和肿瘤学影响,并提供可能的治疗管理概述。我们在 MEDLINE 数据库中进行了非系统性文献回顾,使用以下关键词:部分肾切除术、保留肾单位手术和阳性切缘。我们仅审查了 2002 年 1 月至 2012 年 5 月发表的英文文章。NSS 后 PSMs 的总体发生率为 0%至 7%,开放、腹腔镜和机器人辅助技术之间无显著差异。肿瘤体积越小,PSMs 的风险越高。尽管在临床证据方面尚无明确共识,但局部复发似乎更可能发生在 PSMs 患者中,尤其是那些高分级肿瘤患者。从中期随访研究来看,转移的发展和癌症特异性生存似乎与那些具有阴性手术切缘的患者相当。考虑到局部复发、转移或癌症特异性死亡率的全球低风险,仔细监测可能是大多数 NSS 后 PSMs 患者的最佳治疗选择。